公开(公告)号：US20240060998A1

公开(公告)日：2024-02-22

申请号：US18260914

申请日：2022-02-01

申请人： Medtronic, Inc.

发明人： Narendra K. Simha ,  Sinduja Thinamany ,  James W. Dawson

IPC分类号： G01N33/86 ,  G01N1/28

CPC分类号： G01N33/86 ,  G01N1/28 ,  G01N2333/974 ,  G01N2333/8128 ,  G01N2800/226 ,  G01N2800/50

摘要： A method for determining a patient's likelihood of experiencing a thromboembolic event when receiving an implantable blood contacting medical device. The method includes extracting a sample of blood from the patient. The sample of blood is exposed to a metal, metal alloy, or ceramic in a test tube. The sample of the blood is agitated in the test tube. A thromboembolic marker for the sample in the test tube is measured. If the thromboembolic marker for the sample in the test tube is higher than a predetermined thromboembolic marker threshold, it is determined that the patient is likely to experience the thromboembolic event when receiving the blood contacting implantable medical device.

公开(公告)号：US20160061838A1

公开(公告)日：2016-03-03

申请号：US14758269

申请日：2013-12-27

申请人： SEIKAGAKU CORPORATION

发明人： Maki AIZAWA ,  Toshio ODA ,  Jun AKETAGAWA

IPC分类号： G01N33/579 ,  C01F5/40 ,  C01G45/10 ,  C01F5/30 ,  C01G9/06 ,  C07K14/81 ,  C01F11/24

CPC分类号： G01N33/579 ,  C01F5/30 ,  C01F5/40 ,  C01F11/24 ,  C01G9/06 ,  C01G45/10 ,  C07K5/101 ,  C07K14/8128 ,  G01N2333/8128

摘要： To provide means for reducing reaction interference observed when AT III is subjected to limulus test, whereby the limulus test of antithrombin III can be carried out at high accuracy. Reaction interference observed when AT III is subjected to limulus test can be reduced by subjecting AT III to a protein inactivation treatment in the co-presence of a divalent metal salt.

摘要翻译： 提供减少AT III受鲎试验时观察到反应干扰的手段，从而可以高精度地进行抗凝血酶III的鲎试验。 当AT III进行鲎试验时观察到的反应干扰可以通过使AT III在二价金属盐的共存下进行蛋白质灭活处理来降低。

公开(公告)号：US20110195478A1

公开(公告)日：2011-08-11

申请号：US12849988

申请日：2010-08-04

申请人： Yi-Ting Chen ,  Jau-Song Yu ,  Chien-Lun Chen ,  Yu-Sun Chang

发明人： Yi-Ting Chen ,  Jau-Song Yu ,  Chien-Lun Chen ,  Yu-Sun Chang

IPC分类号： C12N9/96 ,  C12N9/04 ,  C12N9/08 ,  C12N9/10 ,  C12N9/12 ,  C12N9/18 ,  C12N9/88 ,  C12N9/90 ,  C07K14/47 ,  C07K14/775 ,  C07K14/805 ,  C07K16/00 ,  C07K14/745 ,  G01N33/561

CPC分类号： C07K14/775 ,  C07K14/47 ,  C07K14/745 ,  C07K14/805 ,  C12N9/0006 ,  C12N9/0065 ,  C12N9/10 ,  C12N9/12 ,  C12N9/18 ,  C12N9/88 ,  C12N9/90 ,  G01N33/57407 ,  G01N33/57488 ,  G01N2333/775 ,  G01N2333/8128

摘要： The present invention discloses a bladder cancer biomarker and a test method using the same. The biomarker contains at least one of the mentioned 69 compounds, such as apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect.

摘要翻译： 本发明公开了膀胱癌生物标志物及其使用方法。 生物标志物含有载脂蛋白A1（APOA1），载脂蛋白A2（APOA2），过氧氧化还原蛋白2（PRDX2），肝素辅因子2前体（HCII）和血清淀粉样蛋白A-4蛋白（SAA4）等69种化合物中的至少一种， ，存在于受试者的尿标本中。 生物标志物的表达强度可以促进膀胱癌的诊断和膀胱癌侵袭性和恶性肿瘤的评价。 因此，医师可以安排优化的治疗以达到最佳治疗效果。

公开(公告)号：US20070212786A1

公开(公告)日：2007-09-13

申请号：US11540695

申请日：2006-09-29

申请人： Scott Manalis ,  Tzu Loh ,  Michel Godin ,  Nebojsa Milovic ,  Jonathan Behr ,  Aarthi Chandrasekaran ,  Ram Sasisekharan

发明人： Scott Manalis ,  Tzu Loh ,  Michel Godin ,  Nebojsa Milovic ,  Jonathan Behr ,  Aarthi Chandrasekaran ,  Ram Sasisekharan

IPC分类号： G01N33/86

CPC分类号： C12Q1/56 ,  B01L3/5027 ,  G01N27/4145 ,  G01N2333/8128

摘要： In one aspect, the present invention provides a device and method for real-time, direct detection of heparin in buffer and in serum comprising a microfluidic field-effect device as an affinity biosensor. The sensor is based on an electrolyte-insulator-silicon structure, and is manufactured by a standard high-yield silicon microfabrication process. The binding of heparin to the sensor surface induces a change in the insulator-electrolyte surface potential, which is measured as a change in sensor capacitance. To ensure the binding selectivity, protamine and antithrombin III are used as affinity probes.

摘要翻译： 一方面，本发明提供了用于在缓冲液和血清中实时，直接检测肝素的装置和方法，其包括作为亲和生物传感器的微流场效应装置。 该传感器基于电解质 - 绝缘体 - 硅结构，并通过标准的高产率硅微细加工工艺制造。 肝素与传感器表面的结合导致绝缘体 - 电解质表面电位的变化，其被测量为传感器电容的变化。 为了确保结合选择性，使用鱼精蛋白和抗凝血酶III作为亲和探针。

公开(公告)号：US20040043428A1

公开(公告)日：2004-03-04

申请号：US10652372

申请日：2003-08-29

申请人： Roche Diagnostics Corporation

发明人： Enno Adema

IPC分类号： G01N033/53

CPC分类号： G01N33/86 ,  G01N2333/745 ,  G01N2333/8128

摘要： Methods and reagents for determining antithrombin III (AT) in body fluids by adding an AT binding partner to the sample and determining the free AT binding partner.

摘要翻译： 通过向样品中加入AT结合配偶体并确定游离的AT结合配偶体来测定体液中抗凝血酶III（AT）的方法和试剂。

公开(公告)号：USRE35770E

公开(公告)日：1998-04-14

申请号：US574761

申请日：1995-12-19

申请人： Jean Claude Lormeau ,  Maurice Petitou ,  Jean Choay, deceased

发明人： Jean Claude Lormeau ,  Maurice Petitou ,  Jean Choay, deceased

IPC分类号： C08B37/00 ,  A61K31/725 ,  C08B37/10

CPC分类号： C08B37/0078 ,  G01N2333/8128 ,  G01N2400/40

摘要： Oligosaccharides obtainable from heparin including heparinic constituents of molecular weights ranging from 2000 to 50,000. Said fractions have a Yin-Wessler titer and a USP titer in a ratio of at least 30. They consist of chains constituted by no more than 8 saccharidic moities. They possess a strong antithrombotic activity and are then useful as antithrombotic drugs.

公开(公告)号：US5221614A

公开(公告)日：1993-06-22

申请号：US782122

申请日：1991-10-25

申请人： Masayasu Enomoto

发明人： Masayasu Enomoto

IPC分类号： C12Q1/56 ,  G01N33/86

CPC分类号： C12Q1/56 ,  G01N33/86 ,  G01N2333/8128 ,  G01N2333/96444 ,  Y10T436/108331

摘要： A method for determination of biological activity of AT III which comprises mixing a specimen, AT III free-extrinsic coagulation factor-containing plasma, heparin and a prothrombin time-measuring reagent or a factor X-activating reagent and then measuring a coagulation time, and a reagent and plasma to be used therefor.

摘要翻译： 一种测定AT III的生物活性的方法，其包括混合样品，含有AT III游离外因凝血因子的血浆，肝素和凝血酶原时间测定试剂或X因子活化剂，然后测定凝血时间，以及 用于其的试剂和等离子体。

公开(公告)号：US5192689A

公开(公告)日：1993-03-09

申请号：US588924

申请日：1990-09-27

申请人： Hendrik C. Hemker ,  Suzette L. Beguin

发明人： Hendrik C. Hemker ,  Suzette L. Beguin

IPC分类号： C12Q1/56 ,  G01N33/86

CPC分类号： G01N33/86 ,  C12Q1/56 ,  C12Q2337/12 ,  G01N2333/75 ,  G01N2333/8128 ,  G01N2333/974

摘要： A method for determining the endogenous thrombin potential (ETP), which shows how much and for what length of time thrombin has been active in a sample of clotting blood or plasma. The ETP can be used for determining the effectiveness of treatment with antithrombotics of any type. Thus, the ETP determination comprises adding to a sample a thrombin substrate, an activator of thrombin formation, a preparation of proteaseinhibitor and if desired a pharmaceutical for analysis. The thrombin substrate is preferably selected to not completely consume the amount of thrombin generated in the sample, to have a rate of conversion of the substrate which is proportional to the amount of thrombin present and to have a measurable conversion product resulting from the conversion by thrombin. Determination of the amount of conversion product leads to determination of the ETP. The choice of activator determines whether the effect is measured on the intrinsic or extrinsic clotting system, making it possible to determine the effect of the pharmaceutical, which is being analyzed, on various parts of the clotting mechanism.

公开(公告)号：US4918001A

公开(公告)日：1990-04-17

申请号：US903458

申请日：1986-09-04

申请人： Hans-Jurgen Kolde

发明人： Hans-Jurgen Kolde

IPC分类号： C12N9/99 ,  C12Q1/37 ,  C12Q1/56 ,  G01N33/547

CPC分类号： C12Q1/56 ,  C12Q1/37 ,  C12Q2337/12 ,  G01N2333/8128 ,  G01N2333/96444 ,  G01N2333/974

摘要： A method for the determination of a protease inhibitor using a protease which can be inhibited by this inhibitor, and using a substrate for this protease, is described, in which initially a liquid containing the protease inhibitor and the substrate are mixed, then the protease is added, and the rate of hydrolysis of the substrate is determined.

摘要翻译： 描述了使用可以被该抑制剂抑制的蛋白酶和使用该蛋白酶的底物来测定蛋白酶抑制剂的方法，其中最初将含有蛋白酶抑制剂和底物的液体混合，然后将蛋白酶为 并测定底物的水解速率。

公开(公告)号：US4486420A

公开(公告)日：1984-12-04

申请号：US301611

申请日：1981-09-14

申请人： Jean C. Lormeau ,  Jean Choay ,  Jean Goulay, deceased ,  Marie T. by Goulay, heir ,  Marie A. by Goulay, heir ,  Gerard by Goulay, heir

发明人： Jean C. Lormeau ,  Jean Choay ,  Jean Goulay, deceased ,  Marie T. by Goulay, heir ,  Marie A. by Goulay, heir ,  Gerard by Goulay, heir

IPC分类号： A61K31/715 ,  A61P7/02 ,  C08B37/10 ,  G01N33/86

CPC分类号： A61K31/715 ,  C08B37/0075 ,  G01N33/86 ,  G01N2333/8128 ,  G01N2400/40

摘要： The invention pertains to a mucopolysaccharide fraction obtainable from heparin or from fractions including heparinic constituents of molecular weights from 2,000 to 50,000, which has a Yin-Wessler titer which is high relative to the USP titer. It contains components whose molecular weights are less than 10,000, particularly oligosaccharides in the area of 2,000-3,000, comprising from 8 to 12, notably 10 monosaccharide units, among which glucosamine units whose primary positions are sulphated. The last mentioned oligosaccharides include one N-acetyl-glucosamine unit per two units of 2-0-sulphate iduronic acid and per two N-sulphate-glucosamine units, the other saccharide units being of a different nature and including distinct substituents.

摘要翻译： 本发明涉及从肝素或包含分子量为2,000至50,000的肝素成分的馏分获得的粘多糖部分，其具有相对于USP滴度高的Yin-Wessler滴度。 它含有分子量小于10,000的成分，特别是2,000-3,000的寡糖，其中8至12个，特别是10个单糖单元，其中主要位置硫酸化的葡糖胺单元。 最后提及的寡糖包括每两单位2-0-硫酸艾可糖醛酸和每两个硫酸 - 硫酸 - 葡糖胺单位的一个N-乙酰基 - 葡糖胺单元，其它糖单元具有不同的性质并且包括不同的取代基。